Separate names with a comma.
Slide Deck Comparisons Presentation URLs Sept 2023 -...
$SWISF $SKUR.C Sekur Private Data Ltd. Signs Distribution Agreement with VYRE Network - Reaching over 1 million Global Streamers for Its Sekur...
$SWISF News September 05, 2023 Sekur Private Data Ltd. (OTC: SWISF) Advances as Secure Communications Become Vital Against Breaches and Hacks...
Mike The Pike Productions, Inc. (OTC: MIKP) Secures Dealmaker Brandon Milostan of Greenberg Glusker as Entertainment Counsel Published Aug 29,...
Best Seller Coming to the big Screen - Wish update. Mike the Pike Entertainment @MTPPRODS $MIKP Barbara O'Connor's WISH #3 on NYT Bestseller...
STEV - Chart is bottomed and Share Structure update with 6.7mil shares going to restricted. Bullish sign here. Not much recent news, but looks to...
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)...
MindMed on Fox Business Today: https://www.foxbusiness.com/video/6333843103112
Big Update For Sekur Private Data w/ CEO Alain Ghiai [MEDIA] Toronto, Ontario and New York, New York--(Newsfile Corp. - June 14, 2023) - Sekur...
[MEDIA]
Been waiting for a PR for over a year. This is the first in a very long time. Waking up?...
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) – Over 50% of patients dosed across 20...
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy...
MindMed CEO Explains New Vision For Company - TDR Exclusive [MEDIA] Is MindMed, the pioneer in psychedelic medicine, still the leading company...
Agree :)
Video - MindMed update on major depressive disorder data: Rob Barrow, CEO...
LSD to treat severe anxiety? Cleveland Clinic at forefront of psychedelic research...
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)...
New study: My Experiences: Leveraging Digital Technologies to Better Understand Mental Health MindMed listed as collaborator. Sponsored by...
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) April 13, 2023 06:59 ET...
